DekaBank Deutsche Girozentrale grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 19.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 403,194 shares of the company’s stock after purchasing an additional 64,945 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Henry Schein were worth $26,501,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in HSIC. Swedbank purchased a new stake in shares of Henry Schein during the fourth quarter valued at $104,373,000. Norges Bank purchased a new stake in shares of Henry Schein during the fourth quarter valued at $92,675,000. BlackRock Inc. lifted its holdings in shares of Henry Schein by 6.8% during the fourth quarter. BlackRock Inc. now owns 13,083,067 shares of the company’s stock valued at $874,737,000 after purchasing an additional 830,255 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Henry Schein by 400.4% during the fourth quarter. Wells Fargo & Company MN now owns 714,105 shares of the company’s stock valued at $47,745,000 after purchasing an additional 571,408 shares during the last quarter. Finally, Sprucegrove Investment Management Ltd. lifted its holdings in shares of Henry Schein by 105.1% during the fourth quarter. Sprucegrove Investment Management Ltd. now owns 1,020,184 shares of the company’s stock valued at $68,210,000 after purchasing an additional 522,884 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.
Shares of HSIC stock opened at $68.66 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.49 and a quick ratio of 0.92. Henry Schein, Inc. has a fifty-two week low of $49.30 and a fifty-two week high of $74.89. The stock’s 50-day moving average is $65.95 and its two-hundred day moving average is $65.78. The firm has a market cap of $9.77 billion, a P/E ratio of 16.91, a PEG ratio of 3.12 and a beta of 0.86.
Several equities research analysts have recently commented on the company. Barrington Research upped their target price on Henry Schein from $72.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, February 18th. Piper Sandler reissued an “overweight” rating and issued a $83.00 price objective on shares of Henry Schein in a research note on Monday, February 8th. TheStreet downgraded Henry Schein from a “b” rating to a “c+” rating in a research note on Thursday, February 25th. Finally, Robert W. Baird raised Henry Schein from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $70.00 to $79.00 in a research note on Monday, January 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Henry Schein presently has an average rating of “Hold” and a consensus target price of $67.71.
In other news, Director Deborah Derby bought 760 shares of the company’s stock in a transaction on Wednesday, February 24th. The shares were bought at an average cost of $66.22 per share, with a total value of $50,327.20. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.05% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Featured Article: What does an inverted yield curve signify?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.